David Amsellem
Stock Analyst at Piper Sandler
(4.77)
# 124
Out of 5,030 analysts
153
Total ratings
64.46%
Success rate
23.42%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Upgrades: Overweight | $40 → $65 | $50.17 | +29.56% | 17 | Oct 9, 2025 | |
| AMGN Amgen | Maintains: Overweight | $328 → $342 | $298.81 | +14.45% | 5 | Aug 25, 2025 | |
| BIIB Biogen | Maintains: Neutral | $115 → $118 | $143.00 | -17.48% | 2 | Aug 14, 2025 | |
| ABBV AbbVie | Assumes: Overweight | $231 | $229.57 | +0.62% | 1 | Aug 12, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $23.78 | +5.13% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $78.69 | +53.77% | 8 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $154 → $175 | $140.09 | +24.92% | 11 | Jul 31, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $9.28 | +93.97% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $33.96 | +8.95% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $136.06 | +8.04% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $43.63 | +48.98% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $9.24 | -56.71% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $24.48 | -46.90% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.17 | -1.67% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $19.31 | +55.36% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $15.22 | -14.59% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $9.92 | +10.89% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $30.26 | +22.27% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $94.79 | -28.26% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.05 | -50.41% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.86 | +83.73% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $7.08 | +41.24% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.43 | +1,368.53% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $127.94 | -11.68% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $25.90 | +62.16% | 3 | Oct 16, 2023 |
Supernus Pharmaceuticals
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $50.17
Upside: +29.56%
Amgen
Aug 25, 2025
Maintains: Overweight
Price Target: $328 → $342
Current: $298.81
Upside: +14.45%
Biogen
Aug 14, 2025
Maintains: Neutral
Price Target: $115 → $118
Current: $143.00
Upside: -17.48%
AbbVie
Aug 12, 2025
Assumes: Overweight
Price Target: $231
Current: $229.57
Upside: +0.62%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $23.78
Upside: +5.13%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $78.69
Upside: +53.77%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $154 → $175
Current: $140.09
Upside: +24.92%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $9.28
Upside: +93.97%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $33.96
Upside: +8.95%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $136.06
Upside: +8.04%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $43.63
Upside: +48.98%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $9.24
Upside: -56.71%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $24.48
Upside: -46.90%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.17
Upside: -1.67%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $19.31
Upside: +55.36%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $15.22
Upside: -14.59%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $9.92
Upside: +10.89%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $30.26
Upside: +22.27%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $94.79
Upside: -28.26%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.05
Upside: -50.41%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.86
Upside: +83.73%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $7.08
Upside: +41.24%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.43
Upside: +1,368.53%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $127.94
Upside: -11.68%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $25.90
Upside: +62.16%